Screening	B:C0220908
of	O
Conditionally	O
Reprogrammed	O
Patient	O
-	O
Derived	O
Carcinoma	O
Cells	I:C0334227
Identifies	O
ERCC3	O
-	O
MYC	O

Screening	O
of	O
Conditionally	O
Reprogrammed	O
Patient	O
-	O
Derived	O
Carcinoma	B:C0334227
Cells	I:C0334227
Identifies	O
ERCC3	O
-	O
MYC	O

Screening	O
of	O
Conditionally	O
Reprogrammed	O
Patient	O
-	O
Derived	O
Carcinoma	O
Cells	I:C0334227
Identifies	O
ERCC3	B:C1259556
-	O
MYC	O

Screening	O
of	O
Conditionally	O
Reprogrammed	O
Patient	O
-	O
Derived	O
Carcinoma	O
Cells	I:C0334227
Identifies	O
ERCC3	O
-	O
MYC	B:C0080065

Interactions	O
as	O
a	O
Target	O
in	O
Pancreatic	B:C0235974
Cancer	I:C0235974
.	O

Even	O
when	O
diagnosed	B:C1704656
prior	O
to	O
metastasis	O
,	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
)	O
is	O
a	O
devastating	O
malignancy	I:C4282132
with	O
almost	O
90	O
%	O
lethality	O
,	O
emphasizing	O
the	O
need	O
for	O
new	O
therapies	O
optimally	O
targeting	O
the	O
tumors	O
of	O
individual	O
patients	O
.	O

Even	O
when	O
diagnosed	O
prior	O
to	O
metastasis	B:C4255448
,	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
)	O
is	O
a	O
devastating	O
malignancy	I:C4282132
with	O
almost	O
90	O
%	O
lethality	O
,	O
emphasizing	O
the	O
need	O
for	O
new	O
therapies	O
optimally	O
targeting	O
the	O
tumors	O
of	O
individual	O
patients	O
.	O

Even	O
when	O
diagnosed	O
prior	O
to	O
metastasis	O
,	O
pancreatic	B:C1335302
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
)	O
is	O
a	O
devastating	O
malignancy	I:C4282132
with	O
almost	O
90	O
%	O
lethality	O
,	O
emphasizing	O
the	O
need	O
for	O
new	O
therapies	O
optimally	O
targeting	O
the	O
tumors	O
of	O
individual	O
patients	O
.	O

Even	O
when	O
diagnosed	O
prior	O
to	O
metastasis	O
,	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
pancreatic	B:C1335302
ductal	I:C1335302
adenocarcinoma	I:C1335302
)	O
is	O
a	O
devastating	O
malignancy	I:C4282132
with	O
almost	O
90	O
%	O
lethality	O
,	O
emphasizing	O
the	O
need	O
for	O
new	O
therapies	O
optimally	O
targeting	O
the	O
tumors	O
of	O
individual	O
patients	O
.	O

Even	O
when	O
diagnosed	O
prior	O
to	O
metastasis	O
,	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
)	O
is	O
a	O
devastating	B:C4282132
malignancy	I:C4282132
with	O
almost	O
90	O
%	O
lethality	O
,	O
emphasizing	O
the	O
need	O
for	O
new	O
therapies	O
optimally	O
targeting	O
the	O
tumors	O
of	O
individual	O
patients	O
.	O

Even	O
when	O
diagnosed	O
prior	O
to	O
metastasis	O
,	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
)	O
is	O
a	O
devastating	O
malignancy	I:C4282132
with	O
almost	O
90	O
%	O
lethality	B:C3151529
,	O
emphasizing	O
the	O
need	O
for	O
new	O
therapies	O
optimally	O
targeting	O
the	O
tumors	O
of	O
individual	O
patients	O
.	O

Even	O
when	O
diagnosed	O
prior	O
to	O
metastasis	O
,	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
)	O
is	O
a	O
devastating	O
malignancy	I:C4282132
with	O
almost	O
90	O
%	O
lethality	O
,	O
emphasizing	O
the	O
need	O
for	O
new	O
therapies	B:C0087111
optimally	O
targeting	O
the	O
tumors	O
of	O
individual	O
patients	O
.	O

Even	O
when	O
diagnosed	O
prior	O
to	O
metastasis	O
,	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
)	O
is	O
a	O
devastating	O
malignancy	I:C4282132
with	O
almost	O
90	O
%	O
lethality	O
,	O
emphasizing	O
the	O
need	O
for	O
new	O
therapies	O
optimally	O
targeting	O
the	O
tumors	B:C0027651
of	O
individual	O
patients	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	B:C3161035
for	O
study	O
of	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	O
samples	I:C0475358
in	O
culture	O
using	O
short	O
-	O
term	O
culture	O
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	I:C0389995
inhibitor	O
Y	O
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	B:C2603343
of	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	O
samples	I:C0475358
in	O
culture	O
using	O
short	O
-	O
term	O
culture	O
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	I:C0389995
inhibitor	O
Y	O
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	O
of	O
pancreatic	B:C1335302
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	O
samples	I:C0475358
in	O
culture	O
using	O
short	O
-	O
term	O
culture	O
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	I:C0389995
inhibitor	O
Y	O
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	O
of	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	B:C1335302
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	O
samples	I:C0475358
in	O
culture	O
using	O
short	O
-	O
term	O
culture	O
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	I:C0389995
inhibitor	O
Y	O
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	O
of	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	B:C0475358
samples	I:C0475358
in	O
culture	O
using	O
short	O
-	O
term	O
culture	O
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	I:C0389995
inhibitor	O
Y	O
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	O
of	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	O
samples	I:C0475358
in	O
culture	B:C0430400
using	O
short	O
-	O
term	O
culture	O
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	I:C0389995
inhibitor	O
Y	O
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	O
of	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	O
samples	I:C0475358
in	O
culture	O
using	O
short	O
-	O
term	O
culture	B:C0430400
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	I:C0389995
inhibitor	O
Y	O
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	O
of	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	O
samples	I:C0475358
in	O
culture	O
using	O
short	O
-	O
term	O
culture	O
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	B:C0389995
kinase	I:C0389995
inhibitor	O
Y	O
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	O
of	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	O
samples	I:C0475358
in	O
culture	O
using	O
short	O
-	O
term	O
culture	O
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	I:C0389995
inhibitor	B:C0014432
Y	O
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	O
of	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	O
samples	I:C0475358
in	O
culture	O
using	O
short	O
-	O
term	O
culture	O
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	I:C0389995
inhibitor	O
Y	B:C0667301
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	O
of	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	O
samples	I:C0475358
in	O
culture	O
using	O
short	O
-	O
term	O
culture	O
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	I:C0389995
inhibitor	O
Y	O
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	B:C0522537
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	O
of	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
expanding	O
surgical	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
tumor	O
samples	I:C0475358
in	O
culture	O
using	O
short	O
-	O
term	O
culture	O
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	I:C0389995
inhibitor	O
Y	O
-	I:C0667301
27632	I:C0667301
,	O
and	O
creating	O
matched	O
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
(	O
patient	B:C0522537
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
)	O
.	O

These	O
were	O
evaluated	B:C0220825
for	O
sensitivity	O
to	O
a	O
large	O
panel	O
of	O
clinical	O
agents	I:C1254351
,	O
and	O
promising	O
leads	O
further	O
evaluated	O
mechanistically	O
.	O

These	O
were	O
evaluated	O
for	O
sensitivity	O
to	O
a	O
large	O
panel	O
of	O
clinical	B:C1254351
agents	I:C1254351
,	O
and	O
promising	O
leads	O
further	O
evaluated	O
mechanistically	O
.	O

These	O
were	O
evaluated	O
for	O
sensitivity	O
to	O
a	O
large	O
panel	O
of	O
clinical	O
agents	I:C1254351
,	O
and	O
promising	O
leads	O
further	O
evaluated	B:C0220825
mechanistically	O
.	O

Only	O
a	O
small	O
minority	O
of	O
tested	B:C1254351
agents	I:C1254351
was	O
cytotoxic	O
in	O
minimally	O
passaged	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
cultures	O
in	O
vitro	O
Drugs	O
interfering	O
with	O
protein	O
turnover	I:C0597297
and	O
transcription	O
were	O
among	O
most	O
cytotoxic	O
.	O

Only	O
a	O
small	O
minority	O
of	O
tested	O
agents	I:C1254351
was	O
cytotoxic	O
in	O
minimally	O
passaged	O
pancreatic	B:C1335302
ductal	I:C1335302
adenocarcinoma	I:C1335302
cultures	O
in	O
vitro	O
Drugs	O
interfering	O
with	O
protein	O
turnover	I:C0597297
and	O
transcription	O
were	O
among	O
most	O
cytotoxic	O
.	O

Only	O
a	O
small	O
minority	O
of	O
tested	O
agents	I:C1254351
was	O
cytotoxic	O
in	O
minimally	O
passaged	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
cultures	B:C0430400
in	O
vitro	O
Drugs	O
interfering	O
with	O
protein	O
turnover	I:C0597297
and	O
transcription	O
were	O
among	O
most	O
cytotoxic	O
.	O

Only	O
a	O
small	O
minority	O
of	O
tested	O
agents	I:C1254351
was	O
cytotoxic	O
in	O
minimally	O
passaged	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
cultures	O
in	O
vitro	O
Drugs	B:C1254351
interfering	O
with	O
protein	O
turnover	I:C0597297
and	O
transcription	O
were	O
among	O
most	O
cytotoxic	O
.	O

Only	O
a	O
small	O
minority	O
of	O
tested	O
agents	I:C1254351
was	O
cytotoxic	O
in	O
minimally	O
passaged	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
cultures	O
in	O
vitro	O
Drugs	O
interfering	O
with	O
protein	B:C0597297
turnover	I:C0597297
and	O
transcription	O
were	O
among	O
most	O
cytotoxic	O
.	O

Only	O
a	O
small	O
minority	O
of	O
tested	O
agents	I:C1254351
was	O
cytotoxic	O
in	O
minimally	O
passaged	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
cultures	O
in	O
vitro	O
Drugs	O
interfering	O
with	O
protein	O
turnover	I:C0597297
and	O
transcription	B:C0040649
were	O
among	O
most	O
cytotoxic	O
.	O

Among	O
transcriptional	B:C1336789
repressors	I:C1336789
,	O
triptolide	O
,	O
a	O
covalent	O
inhibitor	I:C0243077
of	O
ERCC3	O
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
causing	O
prolonged	O
complete	I:C1516747
regression	I:C1516747
in	O
multiple	O
patient	O
-	I:C0520484
derived	I:C0520484
xenografts	I:C0520484
models	O
resistant	O
to	O
standard	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
therapies	O
.	O

Among	O
transcriptional	O
repressors	I:C1336789
,	O
triptolide	B:C0077274
,	O
a	O
covalent	O
inhibitor	I:C0243077
of	O
ERCC3	O
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
causing	O
prolonged	O
complete	I:C1516747
regression	I:C1516747
in	O
multiple	O
patient	O
-	I:C0520484
derived	I:C0520484
xenografts	I:C0520484
models	O
resistant	O
to	O
standard	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
therapies	O
.	O

Among	O
transcriptional	O
repressors	I:C1336789
,	O
triptolide	O
,	O
a	O
covalent	B:C0243077
inhibitor	I:C0243077
of	O
ERCC3	O
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
causing	O
prolonged	O
complete	I:C1516747
regression	I:C1516747
in	O
multiple	O
patient	O
-	I:C0520484
derived	I:C0520484
xenografts	I:C0520484
models	O
resistant	O
to	O
standard	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
therapies	O
.	O

Among	O
transcriptional	O
repressors	I:C1336789
,	O
triptolide	O
,	O
a	O
covalent	O
inhibitor	I:C0243077
of	O
ERCC3	B:C1259556
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
causing	O
prolonged	O
complete	I:C1516747
regression	I:C1516747
in	O
multiple	O
patient	O
-	I:C0520484
derived	I:C0520484
xenografts	I:C0520484
models	O
resistant	O
to	O
standard	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
therapies	O
.	O

Among	O
transcriptional	O
repressors	I:C1336789
,	O
triptolide	O
,	O
a	O
covalent	O
inhibitor	I:C0243077
of	O
ERCC3	O
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	B:C1515655
vivo	I:C1515655
causing	O
prolonged	O
complete	I:C1516747
regression	I:C1516747
in	O
multiple	O
patient	O
-	I:C0520484
derived	I:C0520484
xenografts	I:C0520484
models	O
resistant	O
to	O
standard	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
therapies	O
.	O

Among	O
transcriptional	O
repressors	I:C1336789
,	O
triptolide	O
,	O
a	O
covalent	O
inhibitor	I:C0243077
of	O
ERCC3	O
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
causing	O
prolonged	B:C1516747
complete	I:C1516747
regression	I:C1516747
in	O
multiple	O
patient	O
-	I:C0520484
derived	I:C0520484
xenografts	I:C0520484
models	O
resistant	O
to	O
standard	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
therapies	O
.	O

Among	O
transcriptional	O
repressors	I:C1336789
,	O
triptolide	O
,	O
a	O
covalent	O
inhibitor	I:C0243077
of	O
ERCC3	O
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
causing	O
prolonged	O
complete	I:C1516747
regression	I:C1516747
in	O
multiple	O
patient	B:C0520484
-	I:C0520484
derived	I:C0520484
xenografts	I:C0520484
models	O
resistant	O
to	O
standard	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
therapies	O
.	O

Among	O
transcriptional	O
repressors	I:C1336789
,	O
triptolide	O
,	O
a	O
covalent	O
inhibitor	I:C0243077
of	O
ERCC3	O
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
causing	O
prolonged	O
complete	I:C1516747
regression	I:C1516747
in	O
multiple	O
patient	O
-	I:C0520484
derived	I:C0520484
xenografts	I:C0520484
models	B:C3161035
resistant	O
to	O
standard	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
therapies	O
.	O

Among	O
transcriptional	O
repressors	I:C1336789
,	O
triptolide	O
,	O
a	O
covalent	O
inhibitor	I:C0243077
of	O
ERCC3	O
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
causing	O
prolonged	O
complete	I:C1516747
regression	I:C1516747
in	O
multiple	O
patient	O
-	I:C0520484
derived	I:C0520484
xenografts	I:C0520484
models	O
resistant	O
to	O
standard	O
pancreatic	B:C1335302
ductal	I:C1335302
adenocarcinoma	I:C1335302
therapies	O
.	O

Among	O
transcriptional	O
repressors	I:C1336789
,	O
triptolide	O
,	O
a	O
covalent	O
inhibitor	I:C0243077
of	O
ERCC3	O
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
causing	O
prolonged	O
complete	I:C1516747
regression	I:C1516747
in	O
multiple	O
patient	O
-	I:C0520484
derived	I:C0520484
xenografts	I:C0520484
models	O
resistant	O
to	O
standard	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
therapies	B:C0087111
.	O

Importantly	O
,	O
triptolide	B:C0077274
showed	O
superior	O
activity	O
in	O
MYC	O
-	I:C0080065
amplified	I:C0080065
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
models	O
and	O
elicited	O
rapid	O
and	O
profound	O
depletion	O
of	O
the	O
oncoprotein	O
MYC	I:C0080065
,	O
a	O
transcriptional	O
regulator	I:C1158770
.	O

Importantly	O
,	O
triptolide	O
showed	O
superior	O
activity	O
in	O
MYC	B:C0080065
-	I:C0080065
amplified	I:C0080065
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
models	O
and	O
elicited	O
rapid	O
and	O
profound	O
depletion	O
of	O
the	O
oncoprotein	O
MYC	I:C0080065
,	O
a	O
transcriptional	O
regulator	I:C1158770
.	O

Importantly	O
,	O
triptolide	O
showed	O
superior	O
activity	O
in	O
MYC	O
-	I:C0080065
amplified	I:C0080065
patient	B:C0522537
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
models	O
and	O
elicited	O
rapid	O
and	O
profound	O
depletion	O
of	O
the	O
oncoprotein	O
MYC	I:C0080065
,	O
a	O
transcriptional	O
regulator	I:C1158770
.	O

Importantly	O
,	O
triptolide	O
showed	O
superior	O
activity	O
in	O
MYC	O
-	I:C0080065
amplified	I:C0080065
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
models	B:C3161035
and	O
elicited	O
rapid	O
and	O
profound	O
depletion	O
of	O
the	O
oncoprotein	O
MYC	I:C0080065
,	O
a	O
transcriptional	O
regulator	I:C1158770
.	O

Importantly	O
,	O
triptolide	O
showed	O
superior	O
activity	O
in	O
MYC	O
-	I:C0080065
amplified	I:C0080065
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
models	O
and	O
elicited	O
rapid	O
and	O
profound	O
depletion	O
of	O
the	O
oncoprotein	B:C0080065
MYC	I:C0080065
,	O
a	O
transcriptional	O
regulator	I:C1158770
.	O

Importantly	O
,	O
triptolide	O
showed	O
superior	O
activity	O
in	O
MYC	O
-	I:C0080065
amplified	I:C0080065
patient	O
-	I:C0522537
derived	I:C0522537
xenografts	I:C0522537
models	O
and	O
elicited	O
rapid	O
and	O
profound	O
depletion	O
of	O
the	O
oncoprotein	O
MYC	I:C0080065
,	O
a	O
transcriptional	B:C1158770
regulator	I:C1158770
.	O

Expression	B:C1171362
of	O
ERCC3	O
and	O
MYC	O
was	O
interdependent	O
in	O
PDACs	O
,	O
and	O
acquired	O
resistance	I:C0013203
to	O
triptolide	O
depended	O
on	O
elevated	O
ERCC3	O
and	O
MYC	O
expression	O
.	O

Expression	O
of	O
ERCC3	B:C1259556
and	O
MYC	O
was	O
interdependent	O
in	O
PDACs	O
,	O
and	O
acquired	O
resistance	I:C0013203
to	O
triptolide	O
depended	O
on	O
elevated	O
ERCC3	O
and	O
MYC	O
expression	O
.	O

Expression	O
of	O
ERCC3	O
and	O
MYC	B:C0080065
was	O
interdependent	O
in	O
PDACs	O
,	O
and	O
acquired	O
resistance	I:C0013203
to	O
triptolide	O
depended	O
on	O
elevated	O
ERCC3	O
and	O
MYC	O
expression	O
.	O

Expression	O
of	O
ERCC3	O
and	O
MYC	O
was	O
interdependent	O
in	O
PDACs	B:C1335302
,	O
and	O
acquired	O
resistance	I:C0013203
to	O
triptolide	O
depended	O
on	O
elevated	O
ERCC3	O
and	O
MYC	O
expression	O
.	O

Expression	O
of	O
ERCC3	O
and	O
MYC	O
was	O
interdependent	O
in	O
PDACs	O
,	O
and	O
acquired	B:C0013203
resistance	I:C0013203
to	O
triptolide	O
depended	O
on	O
elevated	O
ERCC3	O
and	O
MYC	O
expression	O
.	O

Expression	O
of	O
ERCC3	O
and	O
MYC	O
was	O
interdependent	O
in	O
PDACs	O
,	O
and	O
acquired	O
resistance	I:C0013203
to	O
triptolide	B:C0077274
depended	O
on	O
elevated	O
ERCC3	O
and	O
MYC	O
expression	O
.	O

Expression	O
of	O
ERCC3	O
and	O
MYC	O
was	O
interdependent	O
in	O
PDACs	O
,	O
and	O
acquired	O
resistance	I:C0013203
to	O
triptolide	O
depended	O
on	O
elevated	O
ERCC3	B:C1259556
and	O
MYC	O
expression	O
.	O

Expression	O
of	O
ERCC3	O
and	O
MYC	O
was	O
interdependent	O
in	O
PDACs	O
,	O
and	O
acquired	O
resistance	I:C0013203
to	O
triptolide	O
depended	O
on	O
elevated	O
ERCC3	O
and	O
MYC	B:C0080065
expression	O
.	O

Expression	O
of	O
ERCC3	O
and	O
MYC	O
was	O
interdependent	O
in	O
PDACs	O
,	O
and	O
acquired	O
resistance	I:C0013203
to	O
triptolide	O
depended	O
on	O
elevated	O
ERCC3	O
and	O
MYC	O
expression	B:C1171362
.	O

The	B:C3273927
Cancer	I:C3273927
Genome	I:C3273927
Atlas	I:C3273927
analysis	I:C3273927
indicates	O
ERCC3	O
expression	O
predicts	O
poor	O
prognosis	I:C0278252
,	O
particularly	O
in	O
CDKN2A	O
-	I:C2985437
null	I:C2985437
,	O
highly	O
proliferative	I:C0027651
tumors	I:C0027651
.	O

The	O
Cancer	I:C3273927
Genome	I:C3273927
Atlas	I:C3273927
analysis	I:C3273927
indicates	O
ERCC3	B:C1259556
expression	O
predicts	O
poor	O
prognosis	I:C0278252
,	O
particularly	O
in	O
CDKN2A	O
-	I:C2985437
null	I:C2985437
,	O
highly	O
proliferative	I:C0027651
tumors	I:C0027651
.	O

The	O
Cancer	I:C3273927
Genome	I:C3273927
Atlas	I:C3273927
analysis	I:C3273927
indicates	O
ERCC3	O
expression	B:C1171362
predicts	O
poor	O
prognosis	I:C0278252
,	O
particularly	O
in	O
CDKN2A	O
-	I:C2985437
null	I:C2985437
,	O
highly	O
proliferative	I:C0027651
tumors	I:C0027651
.	O

The	O
Cancer	I:C3273927
Genome	I:C3273927
Atlas	I:C3273927
analysis	I:C3273927
indicates	O
ERCC3	O
expression	O
predicts	O
poor	B:C0278252
prognosis	I:C0278252
,	O
particularly	O
in	O
CDKN2A	O
-	I:C2985437
null	I:C2985437
,	O
highly	O
proliferative	I:C0027651
tumors	I:C0027651
.	O

The	O
Cancer	I:C3273927
Genome	I:C3273927
Atlas	I:C3273927
analysis	I:C3273927
indicates	O
ERCC3	O
expression	O
predicts	O
poor	O
prognosis	I:C0278252
,	O
particularly	O
in	O
CDKN2A	B:C2985437
-	I:C2985437
null	I:C2985437
,	O
highly	O
proliferative	I:C0027651
tumors	I:C0027651
.	O

The	O
Cancer	I:C3273927
Genome	I:C3273927
Atlas	I:C3273927
analysis	I:C3273927
indicates	O
ERCC3	O
expression	O
predicts	O
poor	O
prognosis	I:C0278252
,	O
particularly	O
in	O
CDKN2A	O
-	I:C2985437
null	I:C2985437
,	O
highly	B:C0027651
proliferative	I:C0027651
tumors	I:C0027651
.	O

This	O
provides	O
initial	O
preclinical	O
evidence	O
for	O
an	O
essential	O
role	O
of	O
MYC	B:C0080065
-	O
ERCC3	O
interactions	O
in	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
and	O
suggests	O
a	O
new	O
mechanistic	O
approach	O
for	O
disruption	O
of	O
critical	O
survival	O
signaling	O
in	O
MYC	O
-	O
dependent	O
cancers	O
.	O

This	O
provides	O
initial	O
preclinical	O
evidence	O
for	O
an	O
essential	O
role	O
of	O
MYC	O
-	O
ERCC3	B:C1259556
interactions	O
in	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
and	O
suggests	O
a	O
new	O
mechanistic	O
approach	O
for	O
disruption	O
of	O
critical	O
survival	O
signaling	O
in	O
MYC	O
-	O
dependent	O
cancers	O
.	O

This	O
provides	O
initial	O
preclinical	O
evidence	O
for	O
an	O
essential	O
role	O
of	O
MYC	O
-	O
ERCC3	O
interactions	O
in	O
pancreatic	B:C1335302
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
and	O
suggests	O
a	O
new	O
mechanistic	O
approach	O
for	O
disruption	O
of	O
critical	O
survival	O
signaling	O
in	O
MYC	O
-	O
dependent	O
cancers	O
.	O

This	O
provides	O
initial	O
preclinical	O
evidence	O
for	O
an	O
essential	O
role	O
of	O
MYC	O
-	O
ERCC3	O
interactions	O
in	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
and	O
suggests	O
a	O
new	O
mechanistic	O
approach	O
for	O
disruption	O
of	O
critical	O
survival	O
signaling	B:C3537152
in	O
MYC	O
-	O
dependent	O
cancers	O
.	O

This	O
provides	O
initial	O
preclinical	O
evidence	O
for	O
an	O
essential	O
role	O
of	O
MYC	O
-	O
ERCC3	O
interactions	O
in	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
and	O
suggests	O
a	O
new	O
mechanistic	O
approach	O
for	O
disruption	O
of	O
critical	O
survival	O
signaling	O
in	O
MYC	B:C0080065
-	O
dependent	O
cancers	O
.	O

This	O
provides	O
initial	O
preclinical	O
evidence	O
for	O
an	O
essential	O
role	O
of	O
MYC	O
-	O
ERCC3	O
interactions	O
in	O
pancreatic	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
,	O
and	O
suggests	O
a	O
new	O
mechanistic	O
approach	O
for	O
disruption	O
of	O
critical	O
survival	O
signaling	O
in	O
MYC	O
-	O
dependent	O
cancers	B:C0006826
.	O

